INTRODUCTION
============

Norepinephrine is one of the neurotransmitters that has been implicated in the pathogenesis of schizophrenia.[@B1] Norepinephrine is an important chemical messenger in the central and peripheral nervous systems, and it regulates mood, arousal, learning, and autonomic functions.[@B2] Norepinephrine functions are mediated by norepinephrine binding proteins, such as adrenergic receptors and norepinephrine transporter (NET; SLC6A2). The action of norepinephrine is regulated mainly by its uptake into neurons via NET.[@B2][@B3] The NET genes play an important role in central nervous monoaminergic homeostasis, and genetic variation in human NET can influence noradrenergic signaling in the brain.

Human NET is a NaCl-dependent substrate-specific transporter,[@B4] and its reuptake activity is regulated by second messengers and hormones.[@B5][@B6] The gene coding human NET has been assigned to 16q12.2.[@B7] It consists of 15 exons[@B8][@B9] and is a 617-amino acid protein that shows similarity in amino acid sequence to the dopamine transporter and the serotonin transporter.[@B10][@B11][@B12][@B13] Kim et al.[@B14] reported that the 5\'flanking promoter region of the NET gene is approximately 4.7 kb and contains an additional intron of 476 bp. Several potential transcriptional elements are located in this intron and could be important enhancers of transcription and correct splicing.

Several studies have tried to show that functional deficits of the NET gene can cause psychiatric diseases including mood disorder, anxiety disorder, substance disorder, and ADHD. It is thought that noradrenergic dysregulation plays an important role in the pathophysiology of those disorders, and agents related to noradrenergic function can improve the symptoms.[@B15][@B16][@B17] Regarding schizophrenia, however, few reports have been made.

Therefore, we focused on the possibility that the NET gene plays a role in schizophrenia. We investigated three NET single nucleotide polymorphisms (SNPs), T182C (rs2242446), A3081T (rs28386840), and G1287A, to determine whether they play a role in schizophrenia. The T182C and A3081T polymorphisms, located in the 5\'flanking promoter region of the NET gene, could lead to altered transcriptional activity by changing the DNA structure.[@B18] Stöber et al.[@B19] systemically screened the whole coding region of the NET gene and identified 13 DNA sequence variants (five infrequent missense, three silent, and five intronic mutations). Of these variants, a high heterozygosity compared to other markers was observed in the G1287A polymorphism (rs5569), located in exon 9 of the NET gene. Therefore, we tested the hypothesis that the NET gene is involved in the development of schizophrenia or its clinical features. We also hypothesized that the gender difference in clinical course would be related to the differences in the genetic pattern of the disease, and therefore, we planned to examine gender differences in all analyses.

METHODS
=======

Subjects
--------

We recruited 220 patients with schizophrenia who met the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)[@B20] from subjects newly admitted to the Korea University Medical Center Ansan Hospital for acute psychotic symptoms between August 2006 and April 2010. Initial psychiatric interviews were conducted by trained psychiatrists using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).[@B21] The subjects with comorbid diagnoses of schizoaffective disorder, mood disorders, substance-related disorders, or dementia were excluded.

The normal controls consisted of 167 healthy individuals recruited through advertisement. These controls were screened with the SCID-I, non-patient edition.[@B21] Subjects who had any medical/psychiatric illness, familial history of mental illness, or who had scores of ≥10 on the Beck Depression Inventory (BDI)[@B22] or ≥40 on the State-Trait Anxiety Inventory (STAI)[@B23] were excluded.

To assess the severity of a patient\'s psychiatric symptoms, patients were interviewed by trained psychiatrists using the Positive and Negative Syndrome Scale (PANSS)[@B24] and the Korean version of the Calgary depression scale for schizophrenia (K-CDSS). PANSS was published in 1987 by Stanley Kay et al. and is used to measure the symptom severity of patients with schizophrenia. CDSS was developed by Addington et al.[@B25] to evaluate the level of depression in schizophrenia patients. This test is useful in evaluating both relapsed and remitted patients and appears sensitive to change. The Korean version of CDSS was standardized by Kim et al.[@B26] in 2005 and is known to be highly valid and reliable. Treatment dose was determined considering clinical improvement and side effects and was 200-800 mg of chlorpromazine equivalent.

Written informed consent was obtained from all subjects (or caretakers of the patients), and the study protocol was approved by the Ethics Committee of Korea University Ansan Hospital.

DNA analysis and genotyping
---------------------------

Genotypes of the NET gene were analyzed in 220 patients and 167 controls. Genomic DNA was extracted from leukocytes using a commercial DNA extract kit, the Wizard Genomic DNA purification kit (Promega, Madison, WI, USA). Samples were amplified using a thermocycler (GeneAmp PCR system 2700, Applied Biosystems, Foster City, CA, USA).

The NET T182C SNP was genotyped by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods according to the protocol originally described by Inoue et al.[@B15] In brief, the amplification mixture contained 0.5 µL of 100 ng/µL DNA, 2.5 µL of 10x buffer, 0.5 µL of 10mM dNTP mixture, 1 µL primer, 19.375 µL distilled water, and 0.125 µL DNA polymerase (Solgent, Korea). PCR conditions began with an initial 5 min at 95℃, and each cycle consisted of 30 s at 95℃, 30 s at 60℃, and 30 s at 72℃ for 35 cycles. After a final 10 min at 72℃, the reaction was terminated at 4℃. The amplified DNA was digested with the restriction enzyme StyI (New England Biolabs), which cuts at the -182C site, and the product was electrophoresed in 3% agarose gel and stained with ethidium bromide. Homozygous genotypes were identified by the presence of a single 175 bp band (T/T) or bands of 145 and 30 bp (C/C). The heterozygous genotype (T/C) displayed all three band sizes.

The NET A3081T SNP was genotyped by PCR, according to the protocol originally described by Suzuki et al.[@B27] The amplification mixture conditions were the same as with T182C. After an initial 5 min at 95℃, each cycle consisted of 30 s at 95℃, 30 s at 59℃, and 30 s at 72℃ for 36 cycles. After a final 10 min at 72℃, the reaction was terminated at 4℃. The amplified DNA was digested with the restriction enzyme BsrsI (New England Biolabs), which cuts at the -3081A site, and the product was electrophoresed in 3% agarose gel and stained with ethidium bromide. Homozygous genotypes were identified by the presence of 198 and 96 bp bands (A/A) or a single 294 bp band (T/T). The heterozygous genotype (A/T) displayed all three band sizes.

The NET G1287A SNP was genotyped by PCR according to the protocol originally described by Kazuyuki Inoue et al. The amplification mixture conditions were the same as with T182C. After an initial 5 min at 95℃, each cycle consisted of 30 s at 95℃, 30 s at 55℃, and 30 s at 72℃ for 36 cycles. After a final 10 min at 72℃, the reaction was terminated at 4℃. The amplified DNA was digested with the restriction enzyme Sau96I (New England Biolabs), which cuts at the 1287G site, and the product was electrophoresed in 3.7% agarose gel and stained with ethidium bromide. Homozygous genotypes were identified by the presence of 113, 79, 28, and 21 bp bands (G/G) or bands of 113, 100, and 28 bp (A/A). The heterozygous genotype (G/A) displayed all 5 band sizes (the 28 and 21bp fragments were undetectable because of their small size).

Statistical analysis
--------------------

The presence of Hardy-Weinberg equilibrium was tested using a χ^2^ test for goodness of fit. Allele and genotype frequencies in patients with schizophrenia and healthy controls were also evaluated using the χ^2^ test. The pattern of linkage disequilibrium (LD) was investigated for the patient and control groups. Haplotype analysis was performed for the evaluation of haplotype association.

We also examined group differences in the PANSS and K-CDSS scores of acute-phase patients related to the possession of specific alleles of the three polymorphisms using an independent t-test.

These analyses were performed using the Statistical Package for the Social Sciences (SPSS) for Windows (version 21.0; SPSS Inc., Chicago, IL, USA) and SNP analyzer (Istech, Seoul, Republic of Korea). The level of statistical significance was set at p-value\<0.05.

RESULTS
=======

Demographic data
----------------

Demographic data on patients and controls are summarized in [Table 1](#T1){ref-type="table"}. The mean age of schizophrenia patients was 33.10 (9.884) years, and the mean age of the control group was 34.79 (8.815) years. In patients with schizophrenia, the age of disease onset was 27.44 (9.89) years, the duration of illness was 76.44 (9.97) years, and the number of admissions was 1.15 (1.91). There was no significant difference in the mean age or sex between patients with schizophrenia and control subjects. The initial PANSS total score and positive, negative, and general subscores were 96.816 (21.159) and 25.72 (6.845), 23.00 (7.944), 48.10 (10.853), respectively ([Table 1](#T1){ref-type="table"}).

Genotype and allele distribution
--------------------------------

The distributions of the T182C, A3081T, and G1287A polymorphisms in the patients and control groups were in agreement with the Hardy-Weinberg equilibrium and were as follows: T182C (patients, χ^2^=0.284, df=1, p-value=0.594; controls, χ^2^=0.094, df=1, p=0.759; total, χ^2^=0.041, df=1, p-value=0.839); A3081T (patients, χ^2^=0.326, df=1, p-value=0.568; controls, χ^2^=0.055, df=1, p-value=0.815; total, χ^2^=0.322, df=1, p-value=0.570); and G1287A (patients, χ^2^=0.902, df=1, p-value=0.342; controls, χ^2^=0.068, df=1, p=0.795; total, χ^2^=0.377, df=1, p-value=0.539).

Comparing the group of schizophrenia patients with the control group, we found no differences in the genotype or allele distribution. When the male and female subjects were analyzed separately, we also found no significant association of these three polymorphisms with schizophrenia ([Table 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, and [4](#T4){ref-type="table"}). To consider multiple comparison problem, we obtained p-value after Bonferroni correction and found no significant association.

Linkage disequilibrium and haplotype analysis
---------------------------------------------

The LD test revealed that LD was moderately significant between T182C and A3081T (\|D\'\|=0.702, r^2^=0.275, p-value=\<10^-5^) but not between A3081T and G1287A or between T182C and G1287A ([Table 5](#T5){ref-type="table"}). Even though we found no significant LD related with G1287A, we performed a three-locus haplotype analysis. A total of eight haplotype combinations were calculated. Of the eight combinations, only six haplotype combinations with a frequency of at least 5 percent were included in the analysis: T182C-A3081T-G1287A in order T-A-G, C-T-G, T-T-G, C-T-A, T-A-A, T-T-A. The haplotype analysis revealed no significant association between haplotypes and risk for schizophrenia ([Table 6](#T6){ref-type="table"}).

When male and female subjects were analyzed separately, the LD test revealed that LD was also moderately significant between T-182C and A-3081T in both sexes ([Table 5](#T5){ref-type="table"}). In the haplotype analysis according to sex, we found no significant association among haplotype combinations.

Clinical assessment
-------------------

The symptomatic characteristics of acute-phase schizophrenia were determined using PANSS and K-CDSS. Of 220 schizophrenia patients, 163 patients were assessed by PANSS and K-CDSS. We examined the effects of the T182C, A3081T, and G1287A SNPs on these clinical scales using an independent t-test.

No significant differences emerged in most of the analysis ([Table 7](#T7){ref-type="table"}). In the association analysis of G1287A SNPs, patients with the A/A genotype (n=20) showed significantly higher K-CDSS score than patients with the G/A or G/G genotype (p-value=0.024) ([Table 7](#T7){ref-type="table"}). Because of the small sample size, analysis according to gender was not performed.

DISCUSSION
==========

Specific genes and relevant DNA sequence variations involved in the pathogenesis of schizophrenia have not yet been identified. Molecular genetic studies on schizophrenia have suggested that some genes related to the dopaminergic or noradrenergic system could be etiologic factors of schizophrenia,[@B28] but the NET gene has received relatively little attention in this regard.

If NET is related to the pathogenesis of schizophrenia, we can consider some possibilities according to the symptom profile. First, NET dysregulation could be related to dopaminergic overflow causing psychotic symptoms, mainly in the temporal lobe. Also, NET dysregulation could play a role in negative deficit symptoms, even though the mechanism of deficit symptoms in schizophrenia is not fully understood. Siuta et al.[@B29] reported that dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behavior in neuronal rictor null mice, but we do not have clear evidence that NET plays an important role in catecholamine reuptake in the temporal or limbic areas, which are related to psychotic symptoms in schizophrenia. On the contrary, NET is mainly involved with noradrenergic and dopaminergic action in the frontal lobe. Considering the multiplicity of the clinical presentation of schizophrenia, including cognitive decline, loss of spontaneity, and intermittent loss of control, NET should be considered as a factor in schizophrenia.

Several studies have investigated the association between NET gene polymorphisms and various psychiatric disorders, including major depression, bipolar disorder, and substance dependence. However, most of them demonstrated no association with the disease. For schizophrenia, only a few association studies have been performed. Leszczyńska-Rodziewicz et al.[@B1] investigated an association between G1287A and schizophrenia in the Polish population (198 patients and 100 controls) and failed to find any positive findings in either sex.

In the present study, we found no significant differences in the genotype or allele frequency between patients and controls for any of the three NET SNPs. The absence of associations was also observed when male and female subjects were analyzed separately. Our results are in accordance with the Polish study. We also found no significant association between haplotype combinations and schizophrenia in a three-locus haplotype analysis. In relation to clinical assessment with G1287A, A/A carriers showed higher K-CDSS score than patients without the A/A genotype (p-value=0.024). Although this suggests that schizophrenia patients with A/A have more depressive symptoms in the acute phase, the interpretation should be done carefully due to our small sample size and multiple comparison problem.

Currently, no evidence suggests that drugs related to norepinephrine reuptake improve the core symptoms of schizophrenia. If NET is involved in the pathogenesis of schizophrenia, drugs related to NET should improve the clinical symptoms. Antidepressant add-on in patients with schizophrenia is restrictively attempted to reduce depressive symptoms, and antidepressants involving norepinephrine reuptake are not preferred because of the potential risk of aggravating psychotic symptoms. Poyurovsky et al.[@B30] reported that the selective norepinephrine reuptake inhibitor reboxetine did not significantly change patient cognitive performance compared to placebo. However, such trials aim to improve the core deficit symptoms using agents involved in the neurotransmitter mechanism and thought to be important in the treatment of schizophrenia.

This study has several limitations. First, the sample size was not large enough. Second, the subjects of our study were all Korean people. Third, antipsychotic agents were not under experimental control. Even though this study has many weak points, it could serve as an important basis for future study.

Conclusion
----------

Our results suggest that polymorphisms of the NET gene we investigate are not associated with susceptibility to schizophrenia or its clinical features in a Korean population. However, it is significant because it is the first haplotype study to investigate associations between NET gene (SLC6A2) single nucleotide polymorphisms and schizophrenia in a Korean population. Future research with a larger sample size and more genetic markers is needed to replicate our results.
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###### Genotype and allele frequencies in schizophrenia patients and normal controls in total
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###### Genotype and allele frequencies in male schizophrenia patients and male normal controls
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###### Genotype and allele frequencies in female schizophrenia patients and female normal controls
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###### Linkage disequilibrium estimates of NET polymorphisms in the study population with LD map
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NET: norepinephrine transporter, LD: linkage disequilibrium, SNP: single necleotide polymorphism

###### Three-locus haplotype distributions in schizophrenia patients and controls

![](pi-12-551-i006)

^\*^p-value after Bonferroni correction

###### PANSS (positive, negative, general, and total score) and K-CDSS associated with the T182C, A3081T, and G1287A polymorphisms of the NET gene (SLC6A2) in a sample of 163 schizophrenia patients
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PANSS: Positive and Negative Syndrome Scale, K-CDSS: Korean version of Calgary depression scale for schizophrenia
